UPDATE 1-Sarepta shares sink as FDA staff stay sour on muscle disorder drug

April 21 (Reuters) - Sarepta Therapeutics Inc's

shares plunged more than 40 percent after U.S. Food and

Administration staff reviewers maintained their negative outlook

on the company's rare muscle...

Read more